Polypeptides, cells, and methods involving engineered CD16

US11370825B2 · kind B2 · utility

Assignee

• Regents of the University of Minnesota · US

Inventors

• Bruce Kenneth Walcheck · Lino Lakes, US
• Dan Samuel Kaufman · Woodbury, US
• Jianming Wu · Gatineau, CA
• Yawu Jing · Shoreview, US
• Zhenya Ni · Edina, US

Key dates

• Filing date: Apr 19, 2021
• Grant date: Jun 28, 2022
• Expiry date: Apr 19, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure describes, generally, a modified form of CD16, genetically-modified cells that express the modified CD16, and methods that involve the genetically-modified cells. The modified form of CD16 can exhibit increased anti-tumor and/or anti-viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.